8月17日，Argenx SE盘前上涨5%，报919.35美元/股。消息面上，公司宣布其药物efgartigimod（商品名Vyvgart Hytrulo）在一项针对成人自身免疫性肌炎的三期临床试验中达到主要终点，显示出对疾病活动度的显著改善。
试验数据显示，接受efgartigimod治疗的患者在第52周时，平均总改善评分较安慰剂组高出15.4分，治疗获益早在第4周即显现并持续至整个52周治疗期。值得关注的是，该研究也是首个在免疫介导性坏死性肌病（IMNM）这一目前尚无获批疗法的疾病亚型中展现显著改善的三期临床试验，进一步拓展了Vyvgart的潜在适应症版图。此前RBC Capital Markets曾指出，肌炎数据是该股最大的近期催化剂。公司二季度产品净销售额达15.16亿美元，同比增长60%，EPS为7.32美元，均超市场预期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.